Peter,
I followed it since it was spun out from Applied Biosystems (pre acquisition, by PE?) more than a decade ago--before I was a biotechnick. So, luckily, I didn't buy high and sell low, although I did add some at the old $3, when there was financing activity and news about MPSS. I took my losses late last year.
The company made several progressively enormous mistakes not going out for money when it was available. I think they even canceled one set to go at $25 or $12 when the market was tanking. I will tell you that I think the company consistently failed to inform its shareholders just how nearer they were to the still-needs-to be-developed side of being a development-stage company. i lay this at the feet of Sam Eletr.
They HAVE to operate at cash flow or they are dead, so there is now some spending discipline. They are doing the best they can as a contract tissue sample analyzer. This barely keeps the lights on, and will get them to complete prototype protein profiler, hopefully.
Watch for the Protein Profiler. If 2d separations and analysis could be significantly improved, and if PP meets the needs of the market, this invention will be the most certain saving of your investment and at this price a very, very fine, multiple return. But the technology still awaits a feasibility and development collaboration with a manufacturer--I think. The posters on SI who know of such things would be able to make a killing if they were able to forsee commercialization of this technology. If they do foresee its adoption, I hope they will come find me because I won't but irrationaly feel I deserve to.
The next most important event--in my view (some people focus on the Eurpean collaborations and the JV)--is the data from the ISB's use of Megaclone, Megasort etc. in its systems approach to prostate cancer. This is the MOTHER of all feasibility studies for Lynx. The Hood/ABI/lynx/brenner connections runs repeatedly throughout this little company's history; but frankly it was a shock how late in Lynx's life (well too late to support a fiancing) this collaboration occured. As an example of its use by the ISB, and possible limitations and competitors, listen to Hood's presentation at CapCure 9/02.
That is all for now. My family's taken a broadside we are all tying to come to grips with, so I'll be off an on for a while.
Best,
Wilder |
